Eli Lilly (LLY)
(Delayed Data from NYSE)
$859.88 USD
-18.41 (-2.10%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $848.00 -11.88 (-1.38%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 401 - 420 ( 434 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Fourth Quarter Results Felt the Impact of the Zyprexa Patent Expiration.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Raising our CY11 & CY12 estimates in view of strong performance in Q3 CY11........
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Third Quarter Revenue Increased 9% but Heavy Spending Led to Lower Earnings
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Raising our CY11 estimates in view of strong performance in Q2 CY11, though concern remains
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Positive volume Growth with Favorable Currency Trends
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Delays and setbacks on R&D front add further to existing concerns over earnings growth & pipeline productivity.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
First Quarter Results Benefit from Strong International Sales
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
EPS for 2010 Up 7%. Acquisition Dilution and Patent Expirations Could Lower 2011 Earnings.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S